We also noticed that in cell lines treated singly with either crizotinib or foretinib, the pEGFR/EGFR ratio was elevated, which may indicate that the cancer cells compensate for the reduced pMET/MET ratio by increasing the pEGFR/EGFR ratio. The gene discussed is MET; the disease is cancer.